Defendant
2 cases as defendant.
Omni Medsci Inc. is a privately held non-practicing entity (NPE) that asserts patents primarily related to medical device technology. The company was formed in Michigan in October 2010 and operates as a subsidiary of Omni Technology Holdings, Inc., which was established in Michigan in October 2013 and is under the control of its founder, Mohammed N. Islam. No specific employee count or revenue figures are publicly available for Omni Medsci Inc.
As an NPE, Omni Medsci Inc. does not manufacture or sell its own products, but instead seeks to commercialize its patent portfolio through partnerships and licensing. The asserted patents generally relate to medical diagnostic systems, including those controlled by voice commands, and medical device applications utilizing near-infrared or short-wave infrared light sources. The underlying optical technology and inventions are attributed to Mohammed N. Islam, a professor at the University of Michigan, with research interests spanning defense and healthcare applications.
Omni Medsci Inc. demonstrates an active patent-litigation posture, primarily as a patent enforcer. The company has initiated two plaintiff cases in the provided data, targeting companies like Whoop, Inc. in the Delaware District Court and Fossil et al. in the patent-plaintiff-friendly Eastern District of Texas. Concurrently, Omni Medsci Inc. has been a defendant in three cases before the Patent Trial and Appeal Board (PTAB), where its asserted patents have faced validity challenges from entities such as Unified Patents and SAMSUNG ELECTRONICS CO., LTD..
Notable cases include Omni Medsci, Inc. v. Fossil et al., filed in the Eastern District of Texas in late 2024, which also named OnePlus, Oura Health, and Samsung in related complaints, alleging infringement of patents covering wearable devices and physiological parameter measurement. Earlier litigation efforts by Omni Medsci Inc. have also included disputes with Apple Inc., where a federal judge invalidated a patent related to tracking blood-related metrics. Unified Patents has actively sought prior art for Omni Medsci's patents through crowdsourcing contests, characterizing Omni Medsci Inc. as an NPE.
This is an Inter Partes Review (IPR) filed by Unified Patents PTAB Data against Omni Medsci Inc. at the Patent Trial and Appeal Board (PTAB). The petition, concerning patent 11160455, was filed on August 28, 2025, but was not instituted due to procedural reasons.
An IPR case filed by Unified Patents PTAB Data against Omni Medsci Inc. before the Patent Trial and Appeal Board, which was not instituted on procedural grounds.